TD Cowen Starts Centessa Pharmaceuticals (CNTA) at Buy

TD Cowen analyst Stacy Ku initiates coverage on Centessa Pharmaceuticals (NASDAQ: CNTA) with a Buy rating.

The analyst comments "We are initiating coverage of Centessa with a Buy rating, based on ORX750's best in class profile as a transformative therapy in excessive daytime sleepiness. Our KOLs highlight the significant unmet need that should support multiple competitive entrants – given 750's potency and safety, we expect clinical differentiation and commercial success in NT1, NT2, IH and other hypersomnia indications."

For an analyst ratings summary and ratings history on Centessa Pharmaceuticals click here. For more ratings news on Centessa Pharmaceuticals click here.

Shares of Centessa Pharmaceuticals closed at $16.74 yesterday.

You May Also Be Interested In

• Phillips 66, Marathon Merger Talks Collapsed - Semafor
• New Mexico gas pipeline for Oracle data center delayed to 2027
• BofA Securities Resumes American Eagle Outfitters (AEO) at Underperform